- Home
- IVVD vs RENB Comparison
IVVD vs RENB Comparison
Compare IVVD & RENB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- IVVD
- RENB
- Stock Information
- Founded
- IVVD 2020
- RENB 2011
- Country
- IVVD United States
- RENB United States
- Employees
- IVVD N/A
- RENB N/A
- Industry
- IVVD Biotechnology: Pharmaceutical Preparations
- RENB Biotechnology: Pharmaceutical Preparations
- Sector
- IVVD Health Care
- RENB Health Care
- Exchange
- IVVD Nasdaq
- RENB Nasdaq
- Market Cap
- IVVD 123.8M
- RENB 121.3M
- IPO Year
- IVVD 2021
- RENB N/A
- Fundamental
- Price
- IVVD $1.01
- RENB $0.82
- Analyst Decision
- IVVD Strong Buy
- RENB
- Analyst Count
- IVVD 4
- RENB 0
- Target Price
- IVVD $7.89
- RENB N/A
- AVG Volume (30 Days)
- IVVD 8.5M
- RENB 2.2M
- Earning Date
- IVVD 03-27-2025
- RENB 02-19-2025
- Dividend Yield
- IVVD N/A
- RENB N/A
- EPS Growth
- IVVD N/A
- RENB N/A
- EPS
- IVVD N/A
- RENB N/A
- Revenue
- IVVD $11,564,000.00
- RENB N/A
- Revenue This Year
- IVVD N/A
- RENB N/A
- Revenue Next Year
- IVVD $599.08
- RENB N/A
- P/E Ratio
- IVVD N/A
- RENB N/A
- Revenue Growth
- IVVD N/A
- RENB N/A
- 52 Week Low
- IVVD $0.36
- RENB $0.40
- 52 Week High
- IVVD $4.74
- RENB $3.28
- Technical
- Relative Strength Index (RSI)
- IVVD 46.50
- RENB 47.51
- Support Level
- IVVD $0.85
- RENB $0.79
- Resistance Level
- IVVD $1.27
- RENB $1.40
- Average True Range (ATR)
- IVVD 0.23
- RENB 0.13
- MACD
- IVVD -0.08
- RENB -0.00
- Stochastic Oscillator
- IVVD 12.80
- RENB 7.51
About IVVD Invivyd Inc.
Invivyd Inc is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of antibody-based solutions for infectious diseases with pandemic potential. The company is developing antibodies to transcend the limits of naturally occurring immunity and provide superior protection from viral diseases, beginning with COVID-19. The company's product candidates are; ADG20 developed for the treatment and prevention of coronavirus disease, and VYD222, a monoclonal antibody candidate engineered, optimizing for potency and breadth of coverage, as well as providing a higher probability of retaining its utility for a longer duration in an evolving viral landscape.
About RENB Renovaro Biosciences Inc.
Renovaro Inc is a biopharmaceutical company. It is engaged in developing new immunotherapies to combat cancer and developing a predicative artificial intelligence-based diagnostic methodology for the use of earlier cancer detection.